Simvastatin

Simvastatin is a lipophilic statin used primarily as a cholesterol-lowering therapy. As a member of the statin class, it acts by inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway, thereby reducing endogenous cholesterol synthesis and lowering circulating low-density lipoprotein cholesterol. Beyond its established cardiovascular use, simvastatin has also attracted interest in translational and experimental research because inhibition of the mevalonate pathway can influence cell membrane organization, signaling, oxidative stress responses, and other processes relevant to cancer biology and tissue engineering.

In the recent literature provided here, simvastatin appears in several distinct biomedical contexts: as a component of combination anticancer strategies, as a model poorly water-soluble drug in formulation studies, as a payload for biomaterial-based delivery systems in bone regeneration research, and as a medication considered in deprescribing discussions among older adults. These studies collectively reflect simvastatin’s dual identity as both a standard therapeutic agent and a versatile research tool for probing drug delivery, pharmacology, and repurposing potential.